




Instance: composition-en-d4e8178d3a905eabdd581f1645891fb4
InstanceOf: CompositionUvEpi
Title: "Composition for prevymis Package Leaflet"
Description:  "Composition for prevymis Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpbfc2b9171745ce6362620331b99ad218)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - prevymis"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What PREVYMIS is and what it is used for</li>
<li>What you need to know before you take PREVYMIS</li>
<li>How to take PREVYMIS</li>
<li>Possible side effects</li>
<li>How to store PREVYMIS</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What prevymis is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What prevymis is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>PREVYMIS is an antiviral prescription medicine that contains the active substance letermovir. 
PREVYMIS is a medicine for adults who have recently had a stem cell (bone marrow) transplant or a
kidney transplant. The medicine helps stop you from getting ill from CMV ( cytomegalovirus ).
CMV is a virus. For most people, CMV does not hurt them. However, if your immune system is weak
after you get a stem cell transplant or a kidney transplant, you may be at high risk of becoming ill from
CMV.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take prevymis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take prevymis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take PREVYMIS if:
* you are allergic to letermovir or any of the other ingredients of this medicine (listed in section 6).
* you take either of these medicines:<em> 
pimozide - used for Tourette s syndrome</em> 
ergot alkaloids (such as ergotamine and dihydroergotamine) - used for migraine
headaches.
* you take the following herbal product:<em> St. John s wort (Hypericum perforatum)
Do not take PREVYMIS if any of the above apply to you. If you are not sure, talk to your doctor,
pharmacist or nurse before taking PREVYMIS.
If you are taking PREVYMIS with cyclosporine, do not take the following medicines:</em> 
dabigatran - used for blood clots<em> 
atorvastatin, simvastatin, rosuvastatin, pitavastatin  for high cholesterol
Warnings and precautions
If you are also taking a medicine for high cholesterol (see list of medicines in section  Other
medicines and PREVYMIS  below) you must tell your doctor immediately if you have unexplained
muscle aches or pains especially if you feel unwell or have a fever. Your medicine or dose may then
need to be changed. See the package leaflet for your other medicine for further information.
Additional blood tests may be needed to monitor the following medicines:
* Cyclosporine, tacrolimus, sirolimus
* Voriconazole
Children and adolescents
PREVYMIS is not for use in children and adolescents under 18 years old. This is because PREVYMIS
has not been tested in this age group.
Other medicines and PREVYMIS
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other
medicines. This is because PREVYMIS may affect the way other medicines work, and other
medicines may affect how PREVYMIS works. Your doctor or pharmacist will tell you if it is safe to
take PREVYMIS with other medicines.
There are some medicines you must not take with PREVYMIS (see list under  Do not take
PREVYMIS if: ).
There are some additional medicines you must not take with PREVYMIS and cyclosporine (see list
under  If you are taking PREVYMIS with cyclosporine, do not take the following medicines: ).
Also tell your doctor if you are taking any of the following medicines. This is because your doctor
may have to change your medicines or change the dose of your medicines:
* alfentanil - for severe pain
* fentanyl - for severe pain
* quinidine - for abnormal heart rhythms
* cyclosporine, tacrolimus, sirolimus - used to prevent transplant rejection
* voriconazole - for fungal infections
* statins, such as atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin - for
high cholesterol
* glyburide, repaglinide - for high blood sugar
* carbamazepine, phenobarbital, phenytoin - for fits or seizures
* dabigatran, warfarin - used to thin the blood or for blood clots
* midazolam   used as a sedative<br />
</em> amiodarone - used to correct irregular heartbeats
* oral contraceptive steroids-for birth control
* omeprazole, pantoprazole   for stomach ulcers and other stomach
problems
* nafcillin - for bacterial infections
* rifabutin, rifampicin - for mycobacterial infections
* thioridazine - for psychiatric disorders
* bosentan - for high blood pressure in the vessels in the lungs
* efavirenz, etravirine, nevirapine, lopinavir, ritonavir - for HIV
* modafinil - for wakefulness
You can ask your doctor or pharmacist for a list of medicines that may interact with PREVYMIS.
Pregnancy
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for
advice before taking this medicine. PREVYMIS is not recommended in pregnancy. This is because it
has not been studied in pregnancy and it is not known if PREVYMIS will harm your baby while you
are pregnant.
Breast-feeding
If you are breast-feeding or are planning to breast-feed, tell your doctor before taking this medicine.
Breast-feeding is not recommended while taking PREVYMIS. This is because it is not known if
PREVYMIS gets in your breast milk and will be passed to your baby.
Driving and using machines
PREVYMIS may have minor influence on your ability to drive and use machines (see section 4. Possible side effects  below). Some patients have reported fatigue (feeling very tired) or vertigo
(feeling like you are spinning) during treatment with PREVYMIS. If you experience any of these
effects, do not drive or use machines until the effect wears off. 
PREVYMIS contains lactose
PREVYMIS contains lactose monohydrate. If you have been told by your doctor that you have an
intolerance to some sugars, contact your doctor before taking this medicinal product.
PREVYMIS contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that isto say essentially  sodium-
free .</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take prevymis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take prevymis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor
or pharmacist if you are not sure.
How much to take
The recommended dose of PREVYMIS is one 480 mg tablet once a day. If you also take cyclosporine,
your doctor will decrease the dose of PREVYMIS to one 240 mg tablet once a day. 
* Take PREVYMIS at the same time every day.
* Take it with or without food.
How to take
* Swallow the tablet whole with some water. Do not break, crush, or chew the tablet. 
If you take more PREVYMIS than you should
If you take more PREVYMIS than you should, call your doctor straight away.
If you forget to take PREVYMIS
It is very important that you do not miss or skip doses of PREVYMIS.
* If you forget a dose, take it as soon as you remember. However, if it is nearly time for the next
dose, skip the missed dose. Take your next dose at the usual time.
* Do not take two doses of PREVYMIS at the same time to make up for a missed dose.
* If you are not sure what to do, call your doctor or pharmacist.
Do not stop taking PREVYMIS
Do not stop taking PREVYMIS without talking to your doctor first. Do not run out of PREVYMIS.
This will give the medicine the best chance to keep you from becoming ill from CMV after you get a
stem cell transplant or a kidney transplant.</p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common: may affect up to 1 in 10 people
* diarrhoea
* feeling sick (nausea)
* being sick (vomiting)
Uncommon: may affect up to 1 in 100 people
* allergic reaction (hypersensitivity)   the signs may include wheezing, difficulty breathing,
rashes or hives, itchiness, swelling
* loss of appetite
* changes in taste
* headache
* feeling like you are spinning (vertigo)
* stomach ache
* abnormalities in laboratory tests of liver function (i.e. raised levels of liver enzymes)
* muscle spasms
* high blood creatinine - shown in blood tests
* feeling very tired (fatigue)
* swelling of hands or feet
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly via the national reporting
system listed in Appendix V. By reporting side effects you can help provide more information on the
safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store prevymis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store prevymis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister card after EXP.
The expiry date refers to the last day of that month.
This medicine does not require any special temperature storage conditions. Store in the original
package in order to protect from moisture.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help to protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What PREVYMIS contains
The active substance is letermovir. Each film-coated tablet contains 240 mg letermovir or 480 mg
letermovir.
The other ingredients are:
Tablet core
Microcrystalline cellulose (E460), croscarmellose sodium (E468), povidone (E1201), colloidal
anhydrous silica (E551), magnesium stearate (E470b). 
Film-coating
Lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin (E1518), iron oxide
yellow (E172), iron oxide red (only for 480 mg tablets) (E172), carnauba wax (E903). See section 2
 PREVYMIS contains lactose  and  PREVYMIS contains sodium .
What PREVYMIS looks like and contents of the pack
PREVYMIS 240 mg film-coated tablet ( tablet ) is a yellow oval tablet, debossed with  591  on one
side and corporate logo on the other side. The tablet is 16.5 mm long and 8.5 mm wide.
PREVYMIS 480 mg film-coated tablet ( tablet ) is a pink oval, bi-convex tablet, debossed with  595 
on one side and corporate logo on the other side. The tablet is 21.2 mm long and 10.3 mm wide.
The 28x1 tablets are packaged into a carton containing Polyamide/Aluminium/PVC   Aluminium
perforated unit dose blister cards (total of 28 tablets).
Marketing Authorisation Holder
Merck Sharp &amp; Dohme B.V.
Waarderweg 2031 BN Haarlem
The Netherlands
Manufacturer
Organon Heist bv
Industriepark 2220 Heist-op-den-Berg
Belgium
Merck Sharp &amp; Dohme B.V.
Waarderweg 2031 BN Haarlem
The Netherlands
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
MSD Belgium 
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel. + 370 5 278 02 msd_lietuva@merck.com</p>
<p>.: +359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium 
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o.
Tel: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft. 
Tel.: +36 1 888 5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 msdpolska@merck.com
France
MSD France
T l: + 33 (0) 1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska:
Merck Sharp &amp; Dohme d.o.o. 
Tel: + 385 1 6611 croatia_info@merck.com<br />
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@msd.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r. o.
Tel: +421 2 58282dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 .: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: + 371 67364msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency website:
http://www.ema.europa.eu .</p>
<p>Package leaflet: Information for the patient
PREVYMIS 240 mg concentrate for solution for infusion
PREVYMIS 480 mg concentrate for solution for infusion
letermovir
Read all of this leaflet carefully before you are given this medicine because it contains important
information for you.
* Keep this leaflet. You may need to read it again.
* If you have any further questions, ask your doctor, pharmacist, or nurse.
* If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.</p>         </div>"""      



Instance: composition-da-d4e8178d3a905eabdd581f1645891fb4
InstanceOf: CompositionUvEpi
Title: "Composition for prevymis Package Leaflet"
Description:  "Composition for prevymis Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpbfc2b9171745ce6362620331b99ad218)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - prevymis"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Prevymis
3. Sådan skal du tage Prevymis
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What prevymis is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What prevymis is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Prevymis er et antiviralt (virusbekæmpende) receptpligtigt lægemiddel, der indeholder det aktive stof
letermovir. 
Prevymis er et lægemiddel til voksne, som for nylig har gennemgået en stamcelle (knoglemarvs)-
transplantation eller en nyretransplantation. Lægemidlet hjælper med at forhindre, at du bliver syg af
CMV (‘cytomegalovirus’).
CMV er en virus. Hos de fleste personer skader CMV-virus dem ikke. Hvis du har et svækket
immunsystem, efter at du har gennemgået en stamcelletransplantation eller en nyretransplantation, kan
du imidlertid have en høj risiko for CMV-sygdom.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take prevymis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take prevymis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Prevymis</p>
<ul>
<li>
<p>hvis du er allergisk over for letermovir eller et af de øvrige indholdsstoffer i Prevymis (angivet i
punkt 6).</p>
</li>
<li>
<p>hvis du tager et eller flere af disse lægemidler:<em> 
pimozid - anvendes mod Tourettes syndrom</em> 
sekalealkaloider (f.eks. ergotamin og dihydroergotamin) - anvendes mod
migrænehovedpiner.</p>
</li>
<li>
<p>hvis du tager følgende naturlægemiddel:<em> 
perikon (Hypericum perforatum).
Tag ikke Prevymis, hvis noget af ovenstående gælder for dig. Hvis du er i tvivl, så kontakt lægen,
apotekspersonalet eller sygeplejersken, før du begynder at tage Prevymis.
Hvis du tager Prevymis sammen med ciclosporin, må du ikke tage følgende lægemidler:</em> 
dabigatran - anvendes mod blodpropper* 
atorvastatin, simvastatin, rosuvastatin, pitavastatin - mod forhøjet kolesterol.
87
Advarsler og forsigtighedsregler
Hvis du også tager et lægemiddel mod forhøjet kolesterol (se listen over lægemidler i punktet “Brug af
andre lægemidler sammen med Prevymis" nedenfor), skal du straks kontakte din læge, hvis du har
uforklarlige muskelsmerter, især hvis du føler dig utilpas eller har feber. Det kan i så fald være
nødvendigt at ændre din medicin eller din dosis. Se indlægssedlen for anden medicin, du får, for
yderligere oplysninger.
Yderligere blodprøver kan være nødvendige for at monitorere følgende lægemidler:</p>
</li>
<li>
<p>Ciclosporin, tacrolimus, sirolimus</p>
</li>
<li>
<p>Voriconazol.
Børn og unge
Prevymis må ikke anvendes til børn og unge under 18 år. Dette skyldes, at Prevymis ikke er blevet
undersøgt hos denne aldersgruppe.
Brug af andre lægemidler sammen med Prevymis
Fortæl lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget andre
lægemidler eller planlægger at tage andre lægemidler. Årsagen er, at Prevymis kan påvirke, hvordan
andre lægemidler virker, og andre lægemidler kan påvirke, hvordan Prevymis virker. Lægen eller
apotekspersonalet vil fortælle dig, om det er sikkert at tage Prevymis sammen med andre lægemidler.
Der er visse lægemidler, som du ikke må tage sammen med Prevymis (se listen under “Tag ikke
Prevymis hvis:").
Der er yderligere visse lægemidler, som du ikke må tage sammen med Prevymis og cyclosporin (se
listen under "Hvis du tager Prevymis sammen med ciclosporin, må du ikke tage følgende
lægemidler:").
Fortæl det også til lægen, hvis du tager et eller flere af følgende lægemidler. Dette skyldes, at lægen
kan blive nødt til at ændre på din medicin eller ændre på dosis af din medicin:</p>
</li>
<li>
<p>alfentanil - mod stærke smerter</p>
</li>
<li>
<p>fentanyl - mod stærke smerter</p>
</li>
<li>
<p>quinidin - mod unormal hjerterytme</p>
</li>
<li>
<p>ciclosporin, tacrolimus, sirolimus - anvendes til at forebygge afstødning af transplantat</p>
</li>
<li>
<p>voriconazol - mod svampeinfektioner</p>
</li>
<li>
<p>statiner, f.eks. atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin - mod
for højt kolesterol</p>
</li>
<li>
<p>glyburid, repaglinid - mod for højt blodsukker</p>
</li>
<li>
<p>carbamazepin, phenobarbital, phenytoin - mod epileptiske anfald eller krampeanfald</p>
</li>
<li>
<p>dabigatran, warfarin - anvendes som blodfortyndende middel eller mod blodpropper</p>
</li>
<li>
<p>midazolam - anvendes som et beroligende middel (sedativ)  </p>
</li>
<li>
<p>amiodaron - anvendes til at afhjælpe uregelmæssig hjerterytme</p>
</li>
<li>
<p>orale kontraceptive steroider - til prævention</p>
</li>
<li>
<p>omeprazol, pantoprazol - mod mavesår eller andre maveproblemer</p>
</li>
<li>
<p>nafcillin - mod bakterieinfektioner</p>
</li>
<li>
<p>rifabutin, rifampicin - mod mykobakterielle infektioner</p>
</li>
<li>
<p>thioridazin - mod psykiske forstyrrelser</p>
</li>
<li>
<p>bosentan - mod højt blodtryk i blodkarrene i lungerne</p>
</li>
<li>
<p>efavirenz, etravirin, nevapirin, lopinavir, ritonavir - mod hiv</p>
</li>
<li>
<p>modafinil - mod narkolepsi.
Du kan anmode lægen eller apotekspersonalet om en liste over de lægemidler, der kan interagere med
Prevymis.
88
Graviditet
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge
lægen til råds, før du tager dette lægemiddel. Prevymis anbefales ikke under graviditeten, da det ikke
er undersøgt hos gravide. Det er ukendt, om Prevymis vil skade dit ufødte barn, mens du er gravid.
Amning
Hvis du ammer eller planlægger at amme, skal du fortælle det til lægen, før du tager dette lægemiddel.
Undlad at amme, mens du tager Prevymis. Det er ukendt, om Prevymis udskilles i modermælken og
overføres til dit barn.
Trafik- og arbejdssikkerhed
Prevymis kan i mindre grad påvirke din evne til at køre bil og betjene maskiner (se punkt 4
“Bivirkninger" nedenfor). Nogle patienter har rapporteret træthedsfølelse eller vertigo (snurrende
fornemmelse) under behandlingen med Prevymis. Hvis du får nogle af disse bivirkninger, må du ikke
køre bil eller betjene maskiner, før bivirkningerne er aftaget. 
Prevymis indeholder lactose
Prevymis indeholder lactosemonohydrat. Kontakt lægen, før du tager dette lægemiddel, hvis lægen har
fortalt dig, at du ikke tåler visse sukkerarter.
Prevymis indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det
væsentlige natriumfrit.</p>
</li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take prevymis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take prevymis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg
lægen eller apotekspersonalet.
Så meget skal du tage
Den anbefalede dosis af Prevymis er en 480 mg tablet en gang dagligt. Hvis du også tager ciclosporin,
vil lægen nedsætte dosis af Prevymis til en 240 mg tablet en gang dagligt.</p>
<ul>
<li>
<p>Tag Prevymis på samme tidspunkt hver dag.</p>
</li>
<li>
<p>Tag medicinen med eller uden mad.
Sådan skal du tage tabletterne</p>
</li>
<li>
<p>Slug tabletten hel med vand. Du må ikke dele, knuse eller tygge tabletten.
Hvis du har taget for meget Prevymis
Hvis du har taget for meget Prevymis, skal du straks kontakte lægen.
Hvis du har glemt at tage Prevymis
Det er meget vigtigt, at du ikke glemmer at tage eller springer doser af Prevymis over.</p>
</li>
<li>
<p>Hvis du glemmer en dosis, skal du tage den, så snart du kommer i tanke om det. Hvis det dog
næsten er tid til den næste dosis, så spring den manglende dosis over. Tag din næste dosis på det
sædvanlige tidspunkt.</p>
</li>
<li>
<p>Du må ikke tage en dobbeltdosis af Prevymis på samme tid som erstatning for den glemte dosis.</p>
</li>
<li>
<p>Hvis du er i tvivl om, hvad du skal gøre, skal du kontakte lægen eller apotekspersonalet.
Du må ikke holde op med at tage Prevymis
Du må ikke holde op med at tage Prevymis uden først at have talt med lægen. Sørg for ikke at løbe tør
for Prevymis. Derved får lægemidlet de bedste betingelser for at forhindre, at du bliver syg af CMV,
efter at du har gennemgået en stamcelletransplantation eller en nyretransplantation.
Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om.
89</p>
</li>
</ul>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Almindelig: kan forekomme hos op til 1 ud af 10 personer</p>
<ul>
<li>
<p>diarré</p>
</li>
<li>
<p>kvalme</p>
</li>
<li>
<p>opkastning.
Ikke almindelig: kan forekomme hos op til 1 ud af 100 personer</p>
</li>
<li>
<p>allergisk reaktion (overfølsomhed) - symptomerne kan omfatte hvæsende vejrtrækning,
åndedrætsbesvær, udslæt eller nældefeber, kløe, hævelse</p>
</li>
<li>
<p>appetitløshed</p>
</li>
<li>
<p>ændret smagssans</p>
</li>
<li>
<p>hovedpine</p>
</li>
<li>
<p>snurrende fornemmelse (vertigo)</p>
</li>
<li>
<p>mavesmerter</p>
</li>
<li>
<p>unormale prøveresultater for leverfunktion (dvs. forhøjede leverenzymværdier)</p>
</li>
<li>
<p>muskelkramper</p>
</li>
<li>
<p>forhøjet kreatinin i blodet - fremgår af blodprøveresultater</p>
</li>
<li>
<p>træthedsfølelse</p>
</li>
<li>
<p>hævede hænder eller fødder.
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med lægen, apotekspersonalet eller sygeplejersken. Dette
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere
information om sikkerheden af dette lægemiddel.</p>
</li>
</ul>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store prevymis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store prevymis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og blisterkortet efter EXP.
Udløbsdatoen er den sidste dag i den nævnte måned.
Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel. Opbevares i den
originale yderkarton for at beskytte mod fugt.
Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.
90</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Prevymis indeholder:</p>
<ul>
<li>Aktivt stof: letermovir. Hver filmovertrukken tablet indeholder 240 mg letermovir eller 480 mg
letermovir.</li>
<li>
<p>Øvrige indholdsstoffer:
Tabletkerne
Mikrokrystallinsk cellulose (E460), croscarmellosenatrium (E468), povidon (E1201), kolloid
vandfri silica (E551), magnesiumstearat (E470b).
Filmovertræk
Lactosemonohydrat, hypromellose (E464), titandioxid (E171), triacetin (E1518), gul
jernoxid (E172), rød jernoxid (kun til 480 mg tabletter) (E172), carnaubavoks (E903). Se
punkt 2 “Prevymis indeholder lactose" og “Prevymis indeholder natrium".
Udseende og pakningsstørrelser
Prevymis 240 mg filmovertrukken tablet (“tablet") er en gul oval tablet præget med “591" på den ene
side og virksomhedslogo på den anden side. Tabletten er 16,5 mm lang og 8,5 mm bred.
Prevymis 480 mg filmovertrukken tablet (“tablet") er en pink oval, bikonveks tablet præget med “595"
på den ene side og virksomhedslogo på den anden side. Tabletten er 21,2 mm lang og 10,3 mm bred.
28x1 tabletterne er pakket i en karton, der indeholder perforerede enkeltdosisblisterkort
(polyamid/aluminium/PVC-aluminium) (28 tabletter i alt).
Indehaver af markedsføringstilladelsen
Merck Sharp &amp; Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Holland
Fremstiller
Organon Heist bv
Industriepark 30
2220 Heist-op-den-Berg
Belgien
Merck Sharp &amp; Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Holland
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
MSD Belgium 
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel. + 370 5 278 02 47
msd_lietuva@merck.com
България
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium 
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
91
Česká republika
Merck Sharp &amp; Dohme s.r.o.
Tel: +420 233 010 dpoc_czechslovak@merck.com
Magyarország
MSD Pharma Hungary Kft. 
Tel.: +36 1 888 5300
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf.: + 45 4482 4000
dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Ελλάδα
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 00
msdpolska@merck.com
France
MSD France
Tél: + 33 (0) 1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com
Hrvatska:
Merck Sharp &amp; Dohme d.o.o. 
Tel: + 385 1 6611 333
croatia_info@merck.com<br />
România
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@msd.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s. r. o.
Tel: +421 2 58282010
dpoc_czechslovak@merck.com
92
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ.: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: + 371 67364224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}.
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu.
93
Indlægsseddel: Information til patienten
Prevymis 240 mg koncentrat til infusionsvæske, opløsning
Prevymis 480 mg koncentrat til infusionsvæske, opløsning
letermovir
Læs denne indlægsseddel grundigt, inden du får dette lægemiddel, da den indeholder vigtige
oplysninger.</p>
</li>
<li>
<p>Gem indlægssedlen. Du kan få brug for at læse den igen.</p>
</li>
<li>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er mere, du vil vide.</p>
</li>
<li>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, hvis du får bivirkninger, herunder
bivirkninger, som ikke er nævnt i denne indlægsseddel. Se punkt 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk.</p>
</li>
</ul>         </div>"""      





                    
Instance: bundlepackageleaflet-en-d4e8178d3a905eabdd581f1645891fb4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for prevymis Package Leaflet for language en"
Description: "ePI document Bundle for prevymis Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-d4e8178d3a905eabdd581f1645891fb4"
* entry[0].resource = composition-en-d4e8178d3a905eabdd581f1645891fb4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd4e8178d3a905eabdd581f1645891fb4"
* entry[=].resource = mpd4e8178d3a905eabdd581f1645891fb4
                            
                    
Instance: bundlepackageleaflet-da-d4e8178d3a905eabdd581f1645891fb4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for prevymis Package Leaflet for language da"
Description: "ePI document Bundle for prevymis Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-d4e8178d3a905eabdd581f1645891fb4"
* entry[0].resource = composition-da-d4e8178d3a905eabdd581f1645891fb4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd4e8178d3a905eabdd581f1645891fb4"
* entry[=].resource = mpd4e8178d3a905eabdd581f1645891fb4
                            
                    



Instance: mpd4e8178d3a905eabdd581f1645891fb4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product PREVYMIS 240 mg film-coated tablets"
Description: "PREVYMIS 240 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1245/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "PREVYMIS 240 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: d4e8178d3a905eabdd581f1645891fb4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "prevymis"

* status = #current
* mode = #working

* title = "List of all ePIs associated with prevymis"

* subject = Reference(mpbfc2b9171745ce6362620331b99ad218)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#prevymis "prevymis"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-d4e8178d3a905eabdd581f1645891fb4) // prevymis en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-d4e8178d3a905eabdd581f1645891fb4) // prevymis da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-d4e8178d3a905eabdd581f1645891fb4
InstanceOf: List

* insert d4e8178d3a905eabdd581f1645891fb4ListRuleset
    